Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAPN1 | P07384 | 2/20 | 0.46 |
| ▸ | CTSK | P43235 | 7/20 | 0.45 |
| ▸ | CTSS | P25774 | 6/20 | 0.45 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.40 |
| ▸ | CTSL | P07711 | 4/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.37 |
| ▸ | MGLL | Q99685 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4140823 | 0.99 | CAPN1 (0.46) | CAPN1CTSKCTSSCCR1BMP1 | |
| SCHEMBL4135412 | 0.89 | CAPN1 (0.45) | CAPN1CTSKCTSSRENCTSL | |
| SCHEMBL4142973 | 0.89 | CAPN1 (0.48) | CAPN1CTSSCCR1BMP1REN | |
| SCHEMBL4129702 | 0.88 | CAPN1 (0.45) | CAPN1CTSKCTSSRENCTSL | |
| SCHEMBL4141710 | 0.88 | CAPN1 (0.49) | CAPN1CTSKCTSSCCR1BMP1 | |
| SCHEMBL4129767 | 0.87 | CAPN1 (0.47) | CAPN1CCR1BMP1RENCTSL | |
| SCHEMBL4130820 | 0.86 | CAPN1 (0.47) | CAPN1CTSSCCR1BMP1REN | |
| SCHEMBL5429199 | 0.86 | CAPN1 (0.47) | CAPN1CTSKCTSSCCR1BMP1 | |
| SCHEMBL4128185 | 0.86 | CAPN1 (0.46) | CAPN1CTSSCCR1BMP1REN | |
| SCHEMBL4136304 | 0.85 | CAPN1 (0.53) | CAPN1CTSKCTSSCCR1BMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | claimed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
| WO-2007030761-A2 | ACYCLIC 1,4-DIAMINES AND USES THEREOF | SMITHKLINE BEECHAM CORPORATION (US) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | CAPN1 2031/4885CTSK 3473/4885CTSS 3772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.